Last reviewed · How we verify
Epadel, Eicosapentaenoic acid — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Epadel, Eicosapentaenoic acid (Epadel, Eicosapentaenoic acid) — Osaka General Medical Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Epadel, Eicosapentaenoic acid TARGET | Epadel, Eicosapentaenoic acid | Osaka General Medical Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Epadel, Eicosapentaenoic acid CI watch — RSS
- Epadel, Eicosapentaenoic acid CI watch — Atom
- Epadel, Eicosapentaenoic acid CI watch — JSON
- Epadel, Eicosapentaenoic acid alone — RSS
Cite this brief
Drug Landscape (2026). Epadel, Eicosapentaenoic acid — Competitive Intelligence Brief. https://druglandscape.com/ci/epadel-eicosapentaenoic-acid. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab